Compare Incyte Corporation (INCY) vs Lemonade Inc (LMND) Price & Performance

Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.

Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.

Lemonade (LMND) trades at $46.91, up 0.17% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $738 million, and net losses narrowing to -$166 million. Recent news highlights expansion into new states and AI-driven efficiency gains, with management targeting EBITDA profitability by late 2026.

The outlook is mixed: growth and margin improvement offer upside, but persistent losses and high valuation multiples pose risks. Analysts are divided with a consensus price target of $67, suggesting potential upside if profitability targets are met. Key risks include execution on profitability and competitive pressures in the insurtech space.